Jane Street Group LLC trimmed its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 242,602 shares of the company's stock after selling 60,681 shares during the period. Jane Street Group LLC owned about 0.28% of Pediatrix Medical Group worth $3,183,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Northern Trust Corp grew its holdings in Pediatrix Medical Group by 18.0% during the 4th quarter. Northern Trust Corp now owns 966,347 shares of the company's stock worth $12,678,000 after acquiring an additional 147,522 shares during the period. HBK Investments L P acquired a new stake in Pediatrix Medical Group during the 4th quarter worth about $273,000. Oberweis Asset Management Inc. acquired a new stake in Pediatrix Medical Group during the 4th quarter worth about $6,122,000. Hancock Whitney Corp acquired a new stake in Pediatrix Medical Group during the 4th quarter worth about $160,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Pediatrix Medical Group by 9.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 77,393 shares of the company's stock worth $1,016,000 after acquiring an additional 6,753 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. StockNews.com upgraded Pediatrix Medical Group from a "hold" rating to a "buy" rating in a report on Wednesday, January 22nd. UBS Group cut their price objective on shares of Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a research report on Monday, May 12th. Truist Financial cut their price objective on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Macquarie increased their price objective on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Pediatrix Medical Group has an average rating of "Hold" and an average price target of $16.67.
Check Out Our Latest Analysis on Pediatrix Medical Group
Pediatrix Medical Group Stock Down 0.6%
NYSE MD traded down $0.09 during trading hours on Monday, hitting $14.84. The company's stock had a trading volume of 731,044 shares, compared to its average volume of 852,625. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $17.67. The company has a market capitalization of $1.27 billion, a PE ratio of -12.37, a price-to-earnings-growth ratio of 1.74 and a beta of 1.26. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The company's 50-day simple moving average is $13.73 and its two-hundred day simple moving average is $14.11.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.08. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. The business had revenue of $458.36 million for the quarter, compared to analysts' expectations of $451.44 million. During the same quarter last year, the firm earned $0.20 EPS. The firm's revenue for the quarter was down 7.4% compared to the same quarter last year. Research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.
Pediatrix Medical Group Profile
(
Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Further Reading

Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.